It may be necessary to measure the tumor Hsp90 level in each individual cancer patient, group the patients with similar Hsp90 levels and treat different groups of cancer patients with different dosages of the inhibitor in clinical trials. This evidence concerns the gene HSP90AB1 and cancer.